Implications of glycoprotein VI for theranostics

Meinrad Gawaz; Sebastian Vogel; Christina Pfannenberg; Bernd Pichler; Harald Langer; Boris Bigalke

doi:10.1160/TH13-09-0756

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2014; 112(01): 26-31
DOI: 10.1160/TH13-09-0756

Review Article

Schattauer GmbH

Implications of glycoprotein VI for theranostics

Meinrad Gawaz

¹Department of Cardiology & Cardiovascular Medicine, University of Tübingen, Germany

,

Sebastian Vogel

¹Department of Cardiology & Cardiovascular Medicine, University of Tübingen, Germany

,

Christina Pfannenberg

²Department of Diagnostic and Interventional Radiology, University of Tübingen, Germany

,

Bernd Pichler

³Preclinical Imaging, University of Tübingen, Germany

,

Harald Langer

¹Department of Cardiology & Cardiovascular Medicine, University of Tübingen, Germany

,

Boris Bigalke

¹Department of Cardiology & Cardiovascular Medicine, University of Tübingen, Germany

⁴King’s College London, Division of Imaging Sciences and Biomedical Engineering, London, UK

› Author Affiliations

Abstract

Summary

Glycoprotein VI (GPVI), a membrane glycoprotein solely expressed in platelets and megakaryocytes, plays a critical role in thrombus formation due to collagen/GPVI-mediated platelet activation and adhesion. Recent studies have shown that surface expression of GPVI on circulating platelets is enhanced in acute cardiovascular diseases such as myocardial infarction and ischaemic stroke. Increased GPVI levels are associated with poor clinical outcome and are an early indicator for imminent myocardial infarction in patients with chest pain. The soluble form of the dimeric GPVI fusion protein (sGPVI-Fc) binds with high affinity to collagen and atherosclerotic plaque tissue. Non-invasive imaging studies with radiolabelled sGPVI-Fc show specific binding activity to vascular lesions in vivo. Further, sGPVI-Fc has been developed as a new therapeutic platelet-based strategy for lesion-directed antithrombotic therapy. This review summarises the potential of GPVI for diagnostic and therapeutic options based on novel non-invasive molecular imaging modalities to ameliorate care of patients with cardiovascular diseases.

Keywords

Platelets - glycoprotein VI - biomarker - myocardial infarction - stroke - molecular imaging

Full Text

References

References
1 Jackson SP. Arterial thrombosis--insidious, unpredictable and deadly. Nat Med 2011; 17: 1423-1436.
2 Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 08: 1227-1234.
3 Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost 2011; 09 (Suppl. 01) 92-104.
4 Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor?. Blood 2003; 102: 449-461.
5 Clemetson JM, Polgar J, Magnenat E. et al. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J Biol Chem 1999; 274: 29019-29024.
6 Jandrot-Perrus M, Busfield S, Lagrue AH. et al. Cloning, characterisation, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood 2000; 96: 1798-1807.
7 Burkhart JM, Vaudel M, Gambaryan S. et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012; 120: e73-82.
8 Miura Y, Takahashi T, Jung SM. et al. Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen. A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen. J Biol Chem 2002; 277: 46197-46204.
9 Loyau S, Dumont B, Ollivier V. et al. Platelet glycoprotein VI dimerisation, an active process inducing receptor competence, is an indicator of platelet reactivity. Arterioscler Thromb Vasc Biol 2012; 32: 778-785.
10 Al-Tamimi M, Grigoriadis G, Tran H. et al. Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. Blood 2011; 117: 3912-3920.
11 Bender M, Hofmann S, Stegner D. et al. Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases. Blood 2010; 116: 3347-3355.
12 Gardiner EE, Karunakaran D, Shen Y. et al. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost 2007; 05: 1530-1537.
13 Dutting S, Bender M, Nieswandt B. Platelet GPVI: a target for antithrombotic therapy?!. Trends Pharmacol Sci 2012; 33: 583-590.
14 Zahid M, Mangin P, Loyau S. et al. The future of glycoprotein VI as an antithrombotic target. J Thromb Haemost 2012; 10: 2418-2427.
15 Bultmann A, Herdeg C, Li Z. et al. Local delivery of soluble platelet collagen receptor glycoprotein VI inhibits thrombus formation in vivo. Thromb Haemost 2006; 95: 763-766.
16 Bigalke B, Kramer BF, Seizer P. et al. Diagnostic and therapeutic potentials of platelet glycoprotein VI. Semin Thromb Haemost 2010; 36: 203-211.
17 Gawaz M, Konrad I, Hauser AI. et al. Non-invasive imaging of glycoprotein VI binding to injured arterial lesions. Thromb Haemost 2005; 93: 910-913.
18 Geisler T, Grass D, Bigalke B. et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 06: 54-61.
19 Fateh-Moghadam S, Htun P, Tomandl B. et al. Hyperresponsiveness of platelets in ischaemic stroke. Thromb Haemost 2007; 97: 974-978.
20 Stellos K, Bigalke B, Stakos D. et al. Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication. J Thromb Haemost 2010; 08: 205-207.
21 Geisler T, Langer H, Wydymus M. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425.
22 Geisler T, Anders N, Paterok M. et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007; 30: 372-374.
23 Bigalke B, Lindemann S, Ehlers R. et al. Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006; 27: 2165-2169.
24 Bigalke B, Stellos K, Weig HJ. et al. Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS). Basic Res Cardiol 2009; 104: 352-357.
25 Cabeza N, Li Z, Schulz C. et al. Surface expression of collagen receptor Fc receptor-gamma/glycoprotein VI is enhanced on platelets in type 2 diabetes and mediates release of CD40 ligand and activation of endothelial cells. Diabetes 2004; 53: 2117-2121.
26 Bigalke B, Geisler T, Stellos K. et al. Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome. Am Heart J 2008; 156: 193-200.
27 Bigalke B, Haap M, Stellos K. et al. Platelet glycoprotein VI (GPVI) for early identification of acute coronary syndrome in patients with chest pain. Thromb Res 2010; 125: e184-189.
28 Bigalke B, Stellos K, Geisler T. et al. Glycoprotein VI for diagnosis of acute coronary syndrome when ECG is ambiguous. Int J Cardiol 2011; 149: 164-168.
29 Bigalke B, Stellos K, Geisler T. et al. Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease. Clin Res Cardiol 2010; 99: 227-233.
30 Bigalke B, Stellos K, Geisler T. et al. Expression of platelet glycoprotein VI is associated with transient ischaemic attack and stroke. Eur J Neurol 2010; 17: 111-117.
31 Jung SM, Moroi M, Soejima K. et al. Constitutive dimerisation of glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood. J Biol Chem 2012; 287: 30000-30013.
32 Al-Tamimi M, Tan CW, Qiao J. et al. Pathologic shear triggers shedding of vascular receptors: a novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels. Blood 2012; 119: 4311-4320.
33 Bigalke B, Potz O, Kremmer E. et al. Sandwich immunoassay for soluble glycoprotein VI in patients with symptomatic coronary artery disease. Clin Chem 2011; 57: 898-904.
34 Gardiner EE, Al-Tamimi M, Mu FT. et al. Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura. J Thromb Haemost 2008; 06: 1175-1182.
35 Nurden P, Tandon N, Takizawa H. et al. An acquired inhibitor to the GPVI platelet collagen receptor in a patient with lupus nephritis. J Thromb Haemost 2009; 07: 1541-1549.
36 Al-Tamimi M, Gardiner EE, Thom JY. et al. Soluble glycoprotein VI is raised in the plasma of patients with acute ischaemic stroke. Stroke 2011; 42: 498-500.
37 Laske C, Leyhe T, Stransky E. et al. Association of platelet-derived soluble glycoprotein VI in plasma with Alzheimer’s disease. J Psych Res 2008; 42: 746-751.
38 Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
39 Naghavi M, Libby P, Falk E. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003; 108: 1772-1778.
40 Langer HF, Haubner R, Pichler BJ. et al. Radionuclide imaging: a molecular key to the atherosclerotic plaque. J Am Coll Cardiol 2008; 52: 1-12.
41 Massberg S, Konrad I, Bultmann A. et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 2004; 18: 397-399.
42 Schulz C, Penz S, Hoffmann C. et al. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic Res Cardiol 2008; 103: 356-367.
43 Schonberger T, Siegel-Axel D, Bussl R. et al. The immunoadhesin glycoprotein VI-Fc regulates arterial remodelling after mechanical injury in ApoE-/- mice. Cardiovasc Res 2008; 80: 131-137.
44 Bigalke B, Lindemann S, Schonberger T. et al. Ex vivoimaging of injured arteries in rabbits using fluorescence-labelled glycoprotein VI-Fc. Platelets 2012; 23: 1-6.
45 Bigalke B, Pohlmeyer I, Schonberger T. et al. Imaging of injured and atherosclerotic arteries in mice using fluorescence-labelled glycoprotein VI-Fc. Eur J Radiol 2011; 79: e63-69.
46 Wadas TJ, Wong EH, Weisman GR. et al. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 2010; 110: 2858-2902.
47 Bigalke B, Phinikaridou A, Andia ME. et al. PET/CT and MR Imaging in a Murine Model of Progressive Atherosclerosis Using 64Cu-labelled Glycoprotein VI-Fc. Circ Cardiovasc Imaging 2013; 06: 957-964.
48 Moroi M, Jung SM, Okuma M. et al. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989; 84: 1440-1445.
49 Li H, Lockyer S, Concepcion A. et al. The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats. Arterioscler Thromb Vasc Biol 2007; 27: 1199-1205.
50 Mangin PH, Tang C, Bourdon C. et al. A humanized glycoprotein VI (GPVI) mouse model to assess the antithrombotic efficacies of anti-GPVI agents. J Pharm Exp Ther 2012; 341: 156-163.
51 Matsumoto Y, Takizawa H, Gong X. et al. Highly potent anti-human GPVI monoclonal antibodies derived from GPVI knockout mouse immunisation. Thromb Res 2007; 119: 319-329.
52 Ungerer M, Li Z, Baumgartner C. et al. The GPVI - Fc Fusion Protein Revacept Reduces Thrombus Formation and Improves Vascular Dysfunction in Atherosclerosis without Any Impact on Bleeding Times. PloS one 2013; 08: e71193.
53 Bultmann A, Li Z, Wagner S. et al. Impact of glycoprotein VI and platelet adhesion on atherosclerosis--a possible role of fibronectin. J Mol Cell Cardiol 2010; 49: 532-542.
54 Schonberger T, Ziegler M, Borst O. et al. The dimeric platelet collagen receptor GPVI-Fc reduces platelet adhesion to activated endothelium and preserves myocardial function after transient ischaemia in mice. Am J Physiol Cell Physiol 2012; 303: C757-766.
55 Goebel S, Li Z, Vogelmann J. et al. The GPVI-Fc Fusion Protein Revacept Improves Cerebral Infarct Volume and Functional Outcome in Stroke. PloS one 2013; 08: e66960.
56 Ungerer M, Rosport K, Bultmann A. et al. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general haemostasis in humans. Circulation 2011; 123: 1891-1899.
57 Baumer Y, Leder C, Ziegler M. et al. The recombinant bifunctional protein alphaCD133-GPVI promotes repair of the infarcted myocardium in mice. J Thromb Haemost 2012; 10: 1152-1164.
58 Ziegler M, Elvers M, Baumer Y. et al. The bispecific SDF1-GPVI fusion protein preserves myocardial function after transient ischaemia in mice. Circulation 2012; 125: 685-696.
59 Samaha FF, Hibbard C, Sacks J. et al. Density of platelet collagen receptors glycoprotein VI and alpha2beta1 and prior myocardial infarction in human subjects, a pilot study. Med Sci Mon 2005; 11: CR224-229.
60 Bigalke B, Stellos K, Stakos D. et al. Influence of platelet count on the expression of platelet collagen receptor glycoprotein VI (GPVI) in patients with acute coronary syndrome. Thromb Haemost 2009; 101: 911-915.
61 Wurster T, Poetz O, Stellos K. et al. Plasma levels of soluble glycoprotein VI (sGPVI) are associated with ischaemic stroke. Platelets 2013; 24: 560-565.